Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    7.
    发明授权
    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease 有权
    丝氨酸蛋白酶抑制剂,特别是HCV NS3-NS4A蛋白酶

    公开(公告)号:US07906550B2

    公开(公告)日:2011-03-15

    申请号:US12026705

    申请日:2008-02-06

    IPC分类号: A61K31/4025 C07D207/30

    摘要: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

    摘要翻译: 本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。 因此,它们通过干扰丙型肝炎病毒的生命周期起作用,并且作为抗病毒剂是有用的。 本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。

    INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    9.
    发明申请
    INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE 有权
    丝氨酸蛋白酶特异性HCV NS3-NS4A蛋白的抑制剂

    公开(公告)号:US20080125376A1

    公开(公告)日:2008-05-29

    申请号:US12026705

    申请日:2008-02-06

    IPC分类号: A61K38/05 A61P41/00 A61P31/12

    摘要: The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

    摘要翻译: 本发明涉及抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐。 因此,它们通过干扰丙型肝炎病毒的生命周期起作用,并且作为抗病毒剂是有用的。 本发明还涉及包含用于离体使用或用于给予HCV感染患者的所述化合物的药学上可接受的组合物以及制备该化合物的方法。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗患者HCV感染的方法。